About Tosedostat

Tosedostat (toe-SEE-doe-stat) is a novel, orally administered aminopeptidase inhibitor that deprives tumor cells of the amino acid building blocks they need to make proteins necessary for tumor cell survival. Tosedostat has demonstrated significant anti-tumor responses in blood-related cancers and solid tumors in Phase 1-2 clinical trials.

Development Status

There currently are two ongoing Phase 2 investigator-sponsored trials examining the clinical activity of tosedostat.

Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)

You are now leaving website and entering the website.

If you would like to continue, click Continue.

CancelContinue